Breaking News

Dalton, Oryn Therapeutics in Development, Mfg. Pact

To provide cGMP aseptic liquid filling of Oryn’s RA drug in glass vials for Phase I trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dalton Pharma Services has signed a drug development and manufacturing services agreement with Oryn Therapeutics to provide drug development and cGMP aseptic liquid filling of Oryn’s ORTD-1 in glass vials for Phase I clinical studies. ORTD-1 is a first-in-class drug for the treatment of rheumatoid arthritis (RA). ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after nine days of treatment, with remission lasting as long as 2-3 month...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters